Structure Therapeutics Inc. (GPCR) Financial Statements
Free cash flow over the same period: -$224.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GPCRStructure Therapeutics Inc.Follow GPCR — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Research & development | 0.07 | 0.11 | 0.23 | 0.29 | |
| Operating income | -0.10 | -0.16 | -0.18 | -0.26 | |
| Pre-tax income | -0.09 | -0.12 | -0.14 | -0.21 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.09 | -0.12 | -0.14 | -0.21 | |
| Diluted EPS ($) | -0.81 | -0.78 | -0.80 | -0.99 | |
| Diluted shares (bn) | 0.110 | 0.158 | 0.178 | — |
USD billions · SEC XBRL
Structure Therapeutics Inc. — questions
- What is Structure Therapeutics Inc.'s net income?
- -$214.8M over the twelve months to 2026-06-30.
- What is Structure Therapeutics Inc.'s free cash flow?
- -$224.5M over the twelve months to 2026-06-30.
- What are Structure Therapeutics Inc.'s diluted earnings per share?
- $-0.99 over the twelve months to 2026-06-30.
Every figure on this page comes from Structure Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.